samedan logo

 
 
spacer
home > pmps > autumn 2003 > preventative medicine - how advances in technology can protect the integrity of the supply chain
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Preventative Medicine - How Advances in Technology can Protect the Integrity of the Supply Chain

Countering the threat of biological terrorism, preventing the misdirection of drugs and stopping counterfeit goods entering the legitimate supply chain are currently some of the most important and pressing issues for the pharmaceutical industry.

According to the World Health Organization (WHO), up to one in 10 of all the pharmaceuticals in the market today could be counterfeit, implying potentially lethal consequences for millions of consumers. A patient's return to health will be impaired if they do not receive the prescribed drugs for their particular illness or disorder. Worse still, if counterfeit drugs contain harmful agents, the health of patients could be damaged further. There is always the possibility that a patient may be allergic to the chemicals in a counterfeit drug. Participants in the pharmaceutical supply chain are now seriously reviewing their corporate strategies to ensure traceability, compliance, due diligence and risk mitigation can be delivered through their enterprise resource planning (ERP) based software business applications.

Manufacturers and distributors of pharmaceuticals can further mitigate the risks posed by counterfeit goods entering the legitimate supply chain by introducing electronic forms of identification and authentication. Hospitals, dispensaries and pharmacies can utilise electronic authentication to ensure they only stock and administer genuine products, which comply with relevant government safety standards.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Bulent Osman, Sales Director at XKO

Bulent Osman joined XKO in July 2003 as Sales Director. A qualified Accountant, he has over 13 years of sales experience. Before joining XKO, Bulent was employed as the UK Managing Director for Savvion Solutions.

spacer
Bulent Osman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gelomics Partners With Rousselot Biomedical to Create the World’s First, Ready-to-Use 3D Cell Culture Kits Based on X-PURE® GelMA

Irving, United States, 16th November 2022 / Sciad Newswire / Darling Ingredients’ Health Brand, Rousselot, the global leader in collagen-based solutions, and Gelomics, the world-leading provider of fully integrated 3D cell, organoid and tissue culture technologies, have entered into a cobranding partnership. Rousselot Biomedical will supply Gelomics with its X-Pure GelMA (gelatin methacryloyl), a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel™ 3D Tissue Culture System.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement